CARsgen Therapeutics released preliminary clinical data for its in vivo CAR-T candidate, CT1182, showing 5 of 6 patients with R/R B-NHL achieved a response. As of October 31, 2026, the trial reported no dose-limiting toxicities and only Grade 1 CRS, supporting the potential for outpatient administration. The company plans to file for a registrational clinical trial in the first half of 2027.
First clinical data for CT1182 show 3 of 6 patients achieving complete response and 2 partial responses, all ongoing as of the October 31, 2026 cut-off, with no dose-limiting toxicities and only Grade 1 CRS. Positive early efficacy with a favorable safety profile supports the pipeline's value, though the sample is small and the registrational trial filing is only expected in H1 2027.
- ▲ First clinical data for CT1182: 3 CRs and 2 PRs among 6 efficacy-evaluable patients, all responses ongoing as of October 31, 2026
- ▲ No DLTs, no treatment-related SAEs, only Grade 1 CRS observed in DLT-evaluable patients
- ▼ Only six patients enrolled with a median follow-up of about 3.2 months; data are preliminary
- ▼ No effective CAR-T expansion in one TCE-refractory patient due to T cell exhaustion and CD20 antigen loss